In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Follow-on nets $66mm for OmniPod developer Insulet

Executive Summary

Insulet (developed the OmniPod insulin infusion system for diabetes management) netted $66mm through the public sale of 6.9mm common shares (including the overallotment) at $10.25 each.
Deal Industry
  • Medical Devices
    • Infusion Therapy Equipment and Supplies
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies